23andMe Holding Co (ME) Short-Term Debt to Equity

Symbol and logo of brand 23andMe Inc. (ME)

The sector is based on an autonomous product cycle, making it resilient to global crises and transforming it into a defensive asset. Large-scale diagnostic automation allows for the processing of millions of DNA tests, minimizing manual labor. This price chart demonstrates the 0.04 metric, highlighting the role of 23andMe Holding Co. (ME) as a leader in genetics robotics, where high-tech systems fully optimize the preparation of biomaterials.

ME - 23andMe Inc. Short-Term Debt to Capital over the range 07/04/2022 - 04/05/2025

Summary analytical data breakdowns for 23andme.com (ME)

- stock quotes and analyst forecast:
Stock Price 23andMe Inc.|ME - Analyst Consensus Forecast
- market capitalization details:
Market Value 23andMe Holding Co|ME - Business Value
- balance sheet equity data:
Book Value per Share 23andMe|ME - Book Capitalization|Market Value to Book Value Ratio 23andme.com|ME - Aggregate Company Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio 23andMe Holding Co.|ME - Long-Term Liabilities to Capital|Short-Term Debt to Equity 23andMe|ME - Company Total Debt Obligations|Debts to Book Capitalization 23andMe Holding Co|ME - Long-Term Debt Volume|Company Short-Term Debt 23andMe|Quick Liquidity 23andme.com
- earnings and market ratios statistics:
ME - Net Income
Basic company analysis:23andMe Inc.
Product sample of 23andMe

The financial stability of 23andMe Holding Co. (ME) depends on its liquidity balance, which is critical when monetizing genetic data sets for pharma behemoths without incurring capital expenditures. By analyzing the share of short-term loans in the company's equity, an investor assesses the ratio of liabilities due within one year to equity, determining the risk of value dilution or the underutilization of leverage to scale the digital business.

Main competitors

Short-Term Debt to Capital A|Short-Term Debt to Capital Quest Corp (DGX)|Short-Term Debt to Equity Illumina, Inc. ILMN|EXAS: Short-Term Debt to Capital Ratio|Revvity - Short-Term Debt to Capital|BIO - Short-Term Debt to Capital|Anbio Tech (NNNN) - Short-Term Debt to Equity|SHC (Nordion) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio QDEL|Current Liabilities to Capital opko.com OPK|Short-Term Debt to Equity CareDx Health (CDNA)|Short-Term Debt to Capital Coefficient Maravai LifeSciences Holdings|Short-Term Debt to Capital FLGT (Fulgent Corp)|Short-Term Debt to Capital Coefficient Standard BioTools Corp (LAB)|CTKB - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient orasure.com OSUR|exagen.com (XGN) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio MDxHealth S.A.|LUCD (Lucid Diagnostics Inc) - Short-Term Debt to Capital|Short-Term Debt to Capital Prenetics Global Ltd|Short-Term Debt to Equity Insight Molecular Diagnostics (IMDX)|trinitybiotech.com - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital PRPH (ProPhase Labs)|AIMD: Short-Term Debt to Capital Ratio|CODX - Short-Term Debt to Equity|Heart Test Labs (HSCS) - Short-Term Debt to Equity Ratio|BMRA: Short-Term Debt to Capital|Current Liabilities to Capital Cardio Diagnostics Holdings (CDIO)|Short-Term Debt to Equity Ratio VRAX|BJDX: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital AWH|AXDX (Accelerate Diagnostics Inc) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Centogene N.V. CNTG|Enzo Biochem Inc. (ENZ) - Current Liabilities to Capital|FRES - Short-Term Debt to Equity|GENE: Short-Term Debt to Equity|PMD: Short-Term Debt to Capital